伊曲康唑应用于白血病合并侵袭性真菌感染治疗的临床效果观察

目的 探讨伊曲康唑治疗白血病合并侵袭性真菌感染的临床效果.方法 选取2007年8月至2011年9月在我院住院治疗的白血病合并真菌感染患者149例,根据患者在住院期间选择的不同抗真菌药将其分为对照组(n=74)和观察组(n=75).对照组患者给予氟康唑治疗( 400 mg/d),观察组患者给予伊曲康唑治疗(200 mg/d).比较两组患者临床效果以及出现的不良反应.结果 观察组治愈率、显效率、总有效率分别为48.0％、20.0％、94.6％,显著高于对照组(32.4％、16.2％、77.0％),差异均具有统计学意义(P＜0.05).两组患者在治疗期间均未出现严重的不良反应,主要的不良反应为用药后出现肝功能异常,其中对照组发生率为16.2％,观察组发生率为21.3％,两组不良反应发生率差异无统计学意义(P＞0.05).结论 伊曲康唑应用于白血病合并侵袭性真菌感染治疗的临床效果较好,且安全性良好,值得在临床上推广.

Itraconazolo for leukemia complicating with invasive fungal infection

Objective To explore the clinical efficacy of itraconazole for leukemia complicating with invasive fungal infection, Methods 149 leukemia patients complicating with fungal infections in our hospital ware enrolled from August 2007 to September 2011, and divided them into control group （n = 74） and ohservation group （n = 75） according to the antifungal agents they chose. The control group were treated with fluconazole, 400 mg/d, and the observation group were treated with itraconazole, 200 mg/d. Clinical efficacy and adverse reactions were compared between these two groups. Results The cured rate, effective rate and total effective rate were 48,0%, 20.0%, 94.6% in the observation group, respectively, which were significantly higher than that in the control group （32.4%, 16.2%, 77.0%） （P〈0.05）. No serious adverse reactions occurred in both groups during the treatment, The main adverse reaction was liver function abnormality after medication; the occurrence was 16,2% in the control group patients and 21.3% in the observation group, without significant difference （P〉 0.05）, 12onelusions hraconazole for leukemia complicating with invasive fungal infection is clinically efficacious, safe, and should be clinically generalized.